FibroBiologics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for FibroBiologics, Inc. (FBLG) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-11.16-16.49-5.12-1.58-1.17
Depreciation & Amortization0.570.440.090.000.00
Stock Based Compensation2.221.770.270.000.00
Change in Working Capital0.560.490.310.170.00
Change in Accounts Payable1.250.810.530.230.00
Change in Other Working Capital-0.690.080.39-0.060.00
Other Operating Activities-4.090.080.390.000.00
Net Cash from Operating Activities-11.90-6.40-4.07-1.41-1.17
Investing Activities
Capital Expenditures-0.18-0.500.000.000.00
Net Cash from Investing Activities-0.18-0.500.000.000.00
Financing Activities
Debt Repayment-0.570.00-0.53-0.750.00
Common Stock Issued7.510.000.000.291.17
Other Financing Activities0.00-2.65-0.300.290.00
Net Cash from Financing Activities16.9113.795.931.821.17
Summary
Net Change in Cash4.826.901.860.410.00
Cash at Beginning of Period9.162.270.410.000.00
Cash at End of Period13.999.162.270.410.00
Free Cash Flow-12.09-6.90-4.07-1.41-1.17
Supplemental Disclosures
Interest Paid0.020.000.000.000.00